Response to imatinib plus sirolimus in advanced chordoma

Silvia Stacchiotti, A. Marrari, E. Tamborini, E. Palassini, E. Virdis, A. Messina, F. Crippa, C. Morosi, A. Gronchi, S. Pilotti, P. G. Casali

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Imatinib (IM) is active in advanced chordoma. The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma. Patients and methods: Since July 2007, 10 progressive advanced chordoma patients with secondary resistance to IM, and biochemical and/or immunohistochemical evidence of upstream and/or downstream mTOR effector activation, started IM (400 mg/day) plus sirolimus (2 mg/day) on a named basis. Results: The mean treatment duration was 9 months. Of nine patients assessable for response, at 3 months, we had one RECIST partial response (PR), seven stable disease (SD) and one progressive disease (PD). According to Choi criteria applied even to magnetic resonance imaging, we had seven PR (≥10% decrease in size in four cases), one SD and one PD. Seven patients had a positron emission tomography response. The clinical benefit [RECIST complete response + PR + SD ≥6 months] was 89%. Pretreatment mTOR effectors analysis carried out in nine cases was positive in all patients (AKT activation in six patients, S6Sp6 expression/activation in seven). Post-treatment biopsy in one responsive patient confirmed S6 switch off. Conclusion: In addition to PDGFRB, mTOR pathway can be activated in chordomas and the combination of IM plus rapalogs may be effective in IM-resistant chordomas.

Original languageEnglish
Pages (from-to)1886-1894
Number of pages9
JournalAnnals of Oncology
Volume20
Issue number11
DOIs
Publication statusPublished - 2009

Keywords

  • Chordoma
  • Imatinib
  • MTOR
  • Rapamycin
  • Sarcoma
  • Sirolimus

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Response to imatinib plus sirolimus in advanced chordoma'. Together they form a unique fingerprint.

Cite this